R. ScottHarrisMD

Pulmonology • Boston, MA

Critical Care Medicine, Pleural Disease

Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Harris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harris' full profile

Already have an account?

Office
55 Fruit St
Cox 2
Boston, MA 02114
Phone+1 617-726-1721

Fax+1 617-726-6878

Education & Training

Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 1995 - 2000
Tufts Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Massachusetts Medical SchoolClass of 1991

Certifications & Licensure

MA State Medical License 1993 - 2024
FL State Medical License 2014 - 2019

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging Start of enrollment: 2013 Feb 01
Completed
Not Applicable
Imaging Study of the Lungs During an Allergic Asthma Attack Start of enrollment: 2012 May 01
Completed
Not Applicable
T Cell Effector and Regulatory Mechanisms in Asthma Start of enrollment: 2012 Sep 01
Completed
Phase 1
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures Start of enrollment: 2012 Oct 31
Completed
Not Applicable
Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading Start of enrollment: 2010 Apr 01
Withdrawn
Not Applicable
Join now to see all

Publications & Presentations

PubMed

5 citations
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
Patrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, Neil Ahluwalia, Mark Higgins
Journal of Cystic Fibrosis. 2023-05-01
1 citations
Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker.
Tilo Winkler, Puja Kohli, Vanessa J Kelly, Ekaterina G Kehl, Alison S Witkin
Respiratory Research. 2022-12-01
9 citations
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or het...
Gregory S Sawicki, Mark Chilvers, John McNamara, Lutz Naehrlich, Clare Saunders
Journal of Cystic Fibrosis. 2022-07-01